达拉图穆马
颗粒酶
抗体依赖性细胞介导的细胞毒性
CD16
免疫学
流式细胞术
颗粒酶B
癌症研究
免疫分型
CD38
抗体
穿孔素
医学
生物
单克隆抗体
T细胞
免疫系统
CD3型
干细胞
川地34
CD8型
细胞生物学
作者
Christie P.M. Verkleij,Kristine A. Frerichs,Marloes E.C. Broekmans,Carolien Duetz,Chloe A. O’Neill,Wassilis S.C. Bruins,Paola M. Homan‐Weert,Monique C. Minnema,Mark‐David Levin,Annemiek Broijl,Gerard M.J. Bos,Marie José Kersten,Saskia K. Klein,Medya Shikhagaie,Tineke Casneuf,Yann Abraham,Tina Smets,Greet Vanhoof,Diana Cortés‐Selva,Laure van Steenbergen
出处
期刊:HemaSphere
[Wolters Kluwer]
日期:2023-05-01
卷期号:7 (5): e881-e881
被引量:37
标识
DOI:10.1097/hs9.0000000000000881
摘要
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16), but they are also rapidly decreased following initiation of daratumumab treatment. We characterized the NK cell phenotype at baseline and during daratumumab monotherapy by flow cytometry and cytometry by time of flight to assess its impact on response and development of resistance (DARA-ATRA study; NCT02751255). At baseline, nonresponding patients had a significantly lower proportion of CD16+ and granzyme B+ NK cells, and higher frequency of TIM-3+ and HLA-DR+ NK cells, consistent with a more activated/exhausted phenotype. These NK cell characteristics were also predictive of inferior progression-free survival and overall survival. Upon initiation of daratumumab treatment, NK cells were rapidly depleted. Persisting NK cells exhibited an activated and exhausted phenotype with reduced expression of CD16 and granzyme B, and increased expression of TIM-3 and HLA-DR. We observed that addition of healthy donor-derived purified NK cells to BM samples from patients with either primary or acquired daratumumab-resistance improved daratumumab-mediated MM cell killing. In conclusion, NK cell dysfunction plays a role in primary and acquired daratumumab resistance. This study supports the clinical evaluation of daratumumab combined with adoptive transfer of NK cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI